Clinical Trial

Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to establish a registry, screening, and individualized management platform for patients with monogenic diabetes mellitus(MDM) using internet-based and mobile application software. The main questions it aims to answer are: * What are the genetic mutations causing MDM in China (genetic landscape)? * How effective and safe is the individualized, molecular-diagnosis-based management platform for MDM in improving patient outcomes? Participants will: * Register in the MDM platform via mobile app or internet-based software * Undergo genetic screening for MDM diagnosis * Participate in follow-up visits for individualized management and monitoring of blood glucose control and outcomes
Trial Details
NCT Number NCT06746610
Lead Sponsor Tianjin Medical University General Hospital
Conditions Monogenic Diabetes
Enrollment 2,000 participants
Start Date 2022-08-01
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-24